• 1
    Zelinkova Z, Mensink PB, Dees J, et al. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 2010; 45: 4650.
  • 2
    Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 238592.
    Direct Link:
  • 3
    Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab in Crohn`s disease: data from 5000-patients TREAT registry. Gastroenterology 2004; 126: A54.
  • 4
    Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 12558.
  • 5
    Mahadevan U, Terdiman JP, Church J, et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007; 132: A144.
  • 6
    Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 22833.
  • 7
    Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 88195.
  • 8
    Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn`s disease: special situations. J Crohn`s Colitis 2010; 4: 63101.
  • 9
    Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immnosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28: 16974.
  • 10
    Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011 [Epub ahead of print].
  • 11
    Finley WH, Gustavson KH, Hall TM, et al. Birth defect surveillance: Jefferson County, Alabama, and Uppsala County, Sweden. South Med J 1994; 87: 4405.
  • 12
    Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 55163.
  • 13
    Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol 2009; 43: 6136.
  • 14
    Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170: 352833.
  • 15
    Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol 2009; 31: 22336.
  • 16
    Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21: 33659.
  • 17
    Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009; 86: 32844.
  • 18
    Mahadevan U, Kane SV, Church JA, et al. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008; 134: A69.
  • 19
    Cheent K, Nolan J, Shariq S, et al. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn`s disease. J Crohn`s Colitis 2010; 4: 6035.
  • 20
    Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007; 13: 102430.
  • 21
    Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 5239.